We are pleased to welcome HansaBioMed Life Sciences, a global pioneer in extracellular vesicle (EV) and exosome research, as the newest member of the Tehnopol HealthTech Community.<\/p>\n\n\n\n
Established in 2007 in Tallinn, HansaBioMed Life Sciences was the first company dedicated to research in the field of exosomes. This early commitment has positioned the company as a leader in the field, contributing to the development of innovative technologies for EV\/exosomes isolation and characterization. Today, HansaBioMed is a globally recognized name in the exosome and EV field, offering a comprehensive catalog of products and services to researchers and industry partners worldwide. In addition, the company actively participates in EU and nationally funded research projects aimed at exploring the full potential of biologic nanoparticles in emerging fields such as cosmetics or therapeutics.<\/p>\n\n\n\n
With a strong emphasis on scalability and standardization, the company provides end-to-end solutions that meet the needs of both research and applied science.
HansaBioMed\u2019s product portfolio includes:
\u2022 EV standards: high-quality reference materials isolated from various biological sources for EV researchers who need positive control for their diagnostic studies, or their EV detection\/analysis technology
\u2022 EV isolation and purification tools: size-based ultrafiltration methods, size or surface charge-based chromatography solutions, precipitation kits, or immunoaffinity-based isolation methods that can answer various needs depending on the purpose of the researcher
\u2022 Characterization kits and antibodies: ready-to-use tools for analyzing EV markers
\u2022 Custom services: from EV isolation and omics analysis (transcriptomics, genomics, proteomics, lipidomics) to fluorescent EV labeling and surface engineering<\/p>\n\n\n\n
<\/p>\n\n\n\n
HansaBioMed Life Sciences is deeply embedded in the European research landscape. The company has participated in several high-impact EU- and nationally funded projects, including:
\u2022 NAP4DIVE, BOW and EVFoundry \u2013 offering expertise in EV isolation and quality control to support therapeutic innovations.
\u2022 RUP \u2013 led to the development of the current best standard of biologic nanoparticles on the worldwide market.
Cooperation with biotech\/pharma companies has led to the development of scalable purification protocols and integration of EV technologies into the next generation of drug development.
Extracellular vesicles is a broad field, finding potential applications in diagnostics, therapeutics, cosmetics, agriculture, and even further. By the help of its expertise and reputation developed throughout the years, HansaBioMed is always involved in research projects discovering all these alternative areas, delivering innovation to the field.<\/p>\n\n\n\n
<\/p>\n\n\n\n
Public\u2013private collaboration is essential in the exosome field. As a company operating in applied science and product development, HansaBioMed Life Sciences relies on strong partnerships between academia, public research institutions, and industry to drive innovation and ensure the practical application of emerging technologies. These collaborations often take the form of EU- or nationally funded research consortia; academic partners bring deep biological and clinical insights, while HansaBioMed provide expertise, standardized tools and scalable processes that help translate discoveries into real-world applications. This synergy is essential to translate academic findings to validated solutions, reproducible, transferable, and ready for the market.
As a small but highly specialized team, HansaBioMed values collaboration as a core driver of growth. By joining the Tehnopol HealthTech Community, the company is actively seeking new partners for joint research, business development, and knowledge exchange \u2014 especially in areas where complementary expertise can unlock new applications in diagnostics, therapeutics, cosmetics, and beyond.
The company\u2019s location in Tallinn continues to support its mission, benefiting from Estonia\u2019s innovation-friendly infrastructure and its vibrant life sciences ecosystem.<\/p>\n\n\n\n
\u201cWe are not just a commercial company. Our continuous involvement in cutting-edge research projects allows us to stay at the forefront of EV innovation and deliver the most relevant and effective solutions to our customers,\u201d says the HansaBioMed team.<\/p>\n\n\n\n
<\/p>\n\n\n\n
HansaBioMed Life Sciences aims to remain a global leader in exosome and EV research, especially as the field rapidly evolves from basic science to applied solutions in healthcare and biotechnology. By leveraging its expertise, product development pipeline, and collaborative spirit, the company is well-positioned to shape the future of biological nanoparticle technologies.
They are always open for learning and truly believe in improved success through collaboration. HansaBioMed is seeking to collaborate with experts in the fields that they do not have expertise in, to pursue further research or to expand our business.<\/p>\n\n\n\n
We\u2019re proud to support their journey as part of our community and look forward to new breakthroughs ahead.<\/p>\n","protected":false},"excerpt":{"rendered":"
We are pleased to welcome HansaBioMed Life Sciences, a global pioneer in extracellular vesicle (EV) and exosome research, as the newest member of the Tehnopol HealthTech Community. Established in 2007 in Tallinn, HansaBioMed Life Sciences was the first company dedicated to research in the field of exosomes. This early commitment has positioned the company as […]<\/p>\n","protected":false},"author":35,"featured_media":178149,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_s2mail":"yes","footnotes":""},"categories":[194],"tags":[],"class_list":["post-178114","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-technologies"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/posts\/178114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/comments?post=178114"}],"version-history":[{"count":2,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/posts\/178114\/revisions"}],"predecessor-version":[{"id":178116,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/posts\/178114\/revisions\/178116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/media\/178149"}],"wp:attachment":[{"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/media?parent=178114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/categories?post=178114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tehnopol.ee\/en\/wp-json\/wp\/v2\/tags?post=178114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}